Literature DB >> 6241214

Vasoactive intestinal polypeptide decreased in cerebrospinal fluid (CSF) in atypical depression. Vasoactive intestinal polypeptide, cholecystokinin and gastrin in CSF in psychiatric disorders.

A Gjerris, O J Rafaelsen, P Vendsborg, J Fahrenkrug, J F Rehfeld.   

Abstract

Vasoactive intestinal polypeptide (VIP), cholecystokinin (CCK) and gastrin in the cerebrospinal fluid (CSF) were studied in patients with endogenous depression, non-endogenous depression, mania, schizophrenia and a control group. All patients were classified according to ICD-9 and the group of depressions was further classified according to the Newcastle Rating Scales for depression (Carney et al. 1965) (N-I). In the group of non-endogenously depressed patients, CSF-VIP levels (median 16 pmol/l) were found to be significantly lower than those of controls (median = 32 pmol/l) and endogenous depressives (36 pmol/l). In the non-endogenous group, it appeared that the low CSF-VIP was due to a group of patients who, during a past or present depressive episode, had been diagnosed as suffering from endogenous depression. Moreover, this group was clinically characterized by 'dysphoric/hysterical features', 'reversed diurnal variation' (i.e. worse in the evening), and 'lack of clearly circumscribed episodes'. In many aspects this group seems similar to the atypical depressives described as monoamine oxidase inhibitor responders. Concerning CSF-CCK and CSF-gastrin, no significant differences between the examined groups were demonstrated.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6241214     DOI: 10.1016/0165-0327(84)90054-5

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  6 in total

1.  Lateralized hippocampal effects of vasoactive intestinal peptide on learning and memory in rats in a model of depression.

Authors:  Margarita Ivanova; Stiliana Belcheva; Iren Belcheva; Negrin Negrev; Roman Tashev
Journal:  Psychopharmacology (Berl)       Date:  2011-12-08       Impact factor: 4.530

Review 2.  Vasoactive intestinal peptide.

Authors:  S I Said
Journal:  J Endocrinol Invest       Date:  1986-04       Impact factor: 4.256

3.  Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy.

Authors:  J Shlik; E Vasar; J Bradwejn
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

4.  Cerebrospinal fluid concentrations of neuropeptide Y in depressed patients and in controls.

Authors:  A Gjerris; E Widerlöv; L Werdelin; R Ekman
Journal:  J Psychiatry Neurosci       Date:  1992-03       Impact factor: 6.186

5.  Elevated neuroimmune biomarkers in sweat patches and plasma of premenopausal women with major depressive disorder in remission: the POWER study.

Authors:  Giovanni Cizza; Andrea H Marques; Farideh Eskandari; Israel C Christie; Sara Torvik; Marni N Silverman; Terry M Phillips; Esther M Sternberg
Journal:  Biol Psychiatry       Date:  2008-07-26       Impact factor: 13.382

Review 6.  Major depressive disorder is a risk factor for low bone mass, central obesity, and other medical conditions.

Authors:  Giovanni Cizza
Journal:  Dialogues Clin Neurosci       Date:  2011       Impact factor: 5.986

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.